A small molecule inhibitor of the perinucleolar compartment, ML246, attenuates growth and spread of ovarian cancer

Margaux J Kanis; Wenan Qiang; Mario Pineda; Kruti P Maniar; J Julie Kim

doi:10.1186/s40661-018-0064-2

A small molecule inhibitor of the perinucleolar compartment, ML246, attenuates growth and spread of ovarian cancer

Gynecol Oncol Res Pract. 2018 Oct 2:5:7. doi: 10.1186/s40661-018-0064-2. eCollection 2018.

Authors

Margaux J Kanis¹, Wenan Qiang^{2

3}, Mario Pineda¹, Kruti P Maniar³, J Julie Kim^{2

4}

Affiliations

¹ 1Division of Gynecology Oncology, Northwestern University Feinberg School of Medicine, Chicago, IL USA.
² 2Division of Reproductive Science in Medicine, Department of Obstetrics and Gynecology, Northwestern University Feinberg School of Medicine, Chicago, IL USA.
³ 3Department of Pathology, Northwestern University Feinberg School of Medicine, Chicago, IL USA.
⁴ 4Robert H. Lurie Comprehensive Cancer Center, Northwestern University, 303 E. Superior Street, 4-117, Chicago, IL 60611 USA.

Abstract

Background: Ovarian cancer remains a major health problem for women as it is often diagnosed at a late stage with metastatic disease. There are limited therapeutic agents and survival rates remain poor. The perinucleolar compartment (PNC) has been shown to be associated with malignancy and is considered a surrogate phenotypic marker for metastatic cancer cells. A small molecule, ML246, was derived from a screen against PNCs. In this study, the effect of ML246 on ovarian cancer growth and spread was investigated.

Methods: SKOV3 or OVCAR3 cells were treated with ML246 in vitro and PNC was visualized with immunofluorescent staining. Cell invasion was assessed using Matrigel-coated transwell systems. SKOV3 cells were xenografted orthotopically under the ovarian bursa of immunocompromised mice. Additionally, a patient derived ovarian cancer cell line was grafted subcutaneously. Mice were treated with ML246 and tumor growth and spread was assessed.

Results: PNCs were prevalent in the ovarian cancer cell lines OVCAR3 and SKOV3 with higher prevalence in OVCAR3 cells. Treatment with ML246 significantly reduced PNC prevalence in OVCAR3 and SKOV3 cells. Moreover, the invasive activity of both cell lines was significantly inhibited in vitro. Orthotopic implantation of SKOV3 cells resulted in growth of the tumor on the ovary as well as spread of tumor tissues outside of the primary site on organs into the abdominal cavity. Treatment with ML246 decreased the incidence of tumors outside of the ovary. In addition, a patient-derived xenograft (PDX) line was grafted subcutaneously to monitor tumor growth. ML246 significantly attenuated growth of tumors over a 5-week treatment period.

Conclusions: PNC's are present in ovarian cancer cells and treatment with ML246 decreases invasion in vitro and tumor growth and spread in vivo. Additional studies are warranted to determine the efficacy of ML246 as an inhibitor of metastatic disease in ovarian cancer and to determine its precise mechanism of action.

Keywords: ML246; Metarrestin; Ovarian cancer; Perinucleolar compartment.

Abstract

Grants and funding